SEATTLE, Dec. 17, 2018 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that it has been selected as a winner in the sixth annual Fierce Innovation Awards: Life Sciences Edition, an awards program from the leading industry publisher of FierceBiotech and FiercePharma aimed at identifying and showcasing outstanding innovations driving improvements and transformation in the digital health, biotech, and pharma industries. BardyDx earned top honors for the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.
“BardyDx is honored to be recognized for this prestigious distinction. Innovation is the core of our business, and it drives our vision to be the leading cardiac monitoring solutions provider in the industry,” said Gust H. Bardy, MD, BardyDx Founder and Chief Executive Officer. “By addressing the diagnostic shortcomings our clinicians and patients face day-in and day-out, our teams are inspired to deliver revolutionizing solutions like the P-wave focused CAM patch.”
Fierce Innovation Award applicants were evaluated on the merits of their product’s effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. From this year’s strong talent pool, BardyDx was selected among three finalists in the Medical Device Innovation category by a distinguished judging panel of industry leaders for the CAM patch’s potential to profoundly impact patient care.
“Our expert panel of judges reviewed hundreds of applications to find the best of the best,” said Rebecca Willumson, Publisher of FierceBiotech and FiercePharma. “We look for and found cutting edge organizations that have or are in the process of launching new technologies and services that are reinventing what it means to be a part of life sciences.”
The acceptance of this award builds upon the growing market recognition of the innovative P-wave centric features of the CAM patch. Most recently, BardyDx was selected as the winner of the Children’s National Health System Pediatric Medical Device Innovation Competition for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was recently awarded an Innovative Technology contract with Vizient, Inc. upon recommendation of its member-led council of hospital experts for the CAM patch’s ability to enhance clinical care and patient safety.
BardyDx and the full list of featured winners can be found in the 2018 Fierce Innovation Report: Life Sciences Edition.
About Bardy Diagnostics:
Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.
Bardy Diagnostics, Inc.